Alrubicin 10mg Injection (Epirubicin Hydrochloride)

Alrubicin 10mg Injection contains epirubicin, an anthracycline cytotoxic chemotherapy medicine. It works mainly by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cancer-cell death. Epirubicin 10mg injection is used in combination chemotherapy for several cancers, particularly breast cancer, with additional uses depending on local protocols and product labels. It is administered intravenously by trained healthcare professionals and can cause significant bone-marrow suppression and cumulative heart toxicity. The lifetime anthracycline exposure of the patient is therefore important. Alrubicin 10mg Injection is a prescription medicine and requires careful monitoring of blood counts, heart function, liver function, and the infusion site.

Epirubicin 10mg injection is commonly used as part of combination chemotherapy for breast cancer, including adjuvant treatment in appropriate patients. It may also be incorporated into specialist regimens for other solid tumors and hematological malignancies depending on regional approvals and institutional protocols. The exact dose and combination depend on the cancer type, treatment intent, previous anthracycline exposure, heart function, liver function, and bone marrow reserve. Anthracycline dosing is not interchangeable on a milligram-for-milligram basis without protocol guidance.

Alrubicin 10mg is an anthracycline chemotherapy medicine. It intercalates between DNA base pairs, inhibits topoisomerase II, and generates free-radical-mediated cellular injury. These actions interfere with DNA replication and can kill rapidly dividing cancer cells. Cardiac tissue and bone marrow can also be damaged, explaining cumulative cardiomyopathy and myelosuppression. Epirubicin 10mg is a vesicant, so leakage outside the vein can cause severe local tissue injury.

Evidence context: The studies below are pivotal or widely cited evidence supporting the Epirubicin 10mg injection in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Alrubicin 10mg injection may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Neutropenia / leukopenia
• Anemia
• Thrombocytopenia
• Nausea and vomiting
• Hair loss
• Mouth sores
• Fatigue
• Temporary red-colored urine after treatment

Serious side effects

• Cardiomyopathy / heart failure
• Severe infection from myelosuppression
• Extravasation with tissue necrosis
• Secondary leukemia

Epirubicin injection is dosed according to the chemotherapy protocol and body surface area; there is no single dose appropriate for every cancer. In adjuvant breast cancer regimens, labelled doses are commonly given on day 1 of repeated cycles or split across defined cycle days, depending on the regimen. Dose modification is required for hepatic impairment and severe myelosuppression. The 10 mg vial is a product presentation, not a patient dose. Administration must be intravenous through a secure line because extravasation can cause severe tissue necrosis.

Administration guidance: Alrubicin 10mg injection must be administered intravenously by an experienced oncology professional. The dose is calculated from the chemotherapy regimen and body surface area and may be modified according to blood counts, liver function, and previous treatment. The medicine is vesicant: if it leaks outside the vein, severe tissue damage can occur. Tell the nurse immediately about burning, pain, redness, or swelling at the infusion site. Blood counts are checked before treatment, and heart function may be assessed before and during therapy, particularly as cumulative anthracycline exposure increases. Do not self-administer this medicine.​​

If a scheduled dose is missed, the oncology team must decide the new treatment date based on the chemotherapy protocol, blood counts, and organ function. Never compensate with an extra dose.

Check CBC and liver function before treatment. Assess baseline cardiac function and repeat as clinically indicated, especially with increasing cumulative anthracycline exposure or other cardiotoxic therapies. Monitor the infusion site continuously for pain, burning, swelling, or erythema. Record prior anthracycline exposure.

Practical monitoring checklist

• Complete blood count (CBC) at the label/protocol-recommended intervals
• Liver function according to baseline risk and treatment label
• Cardiac assessment/ECG or ejection-fraction monitoring when clinically indicated
  

• Pfizer Farmorubicin India Local Product Document (2024/current). https://labeling.pfizer.com/ShowLabeling.aspx?id=15025​
• FDA Ellence/epirubicin 10mg Injection prescribing information. https://labeling.pfizer.com/showlabeling.aspx?id=657​
• NCI Drug Dictionary: Epirubicin 10mg Injection. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epirubicin-hydrochloride​
• ScienceDirect. Epirubicin Injection. https://www.sciencedirect.com/topics/neuroscience/epirubicin​
• MDPI. Development of Epirubicin 10mg Injection loaded biocompatible polymers. https://www.mdpi.com/2073-4360/13/8/1212​